ロード中...
Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study
Conventional treatment for brain metastases (BM) is whole-brain radiotherapy (WBRT). Efficacy is poor. It might be increased by a potent radiosensitiser such as gemcitabine which is believed to cross the disrupted blood–brain barrier. Primary objective of this study was to determine the maximum tole...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group
2005
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2361913/ https://ncbi.nlm.nih.gov/pubmed/15714201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602444 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|